Sfoglia per Autore
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival
2010-01-01 Menna, P; Salvatorelli, E; Minotti, G
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment
2011-01-01 Salvatorelli, E.; Gonzalez Paz, O.; Covino, E.; Chello, M.; Singer, J.; Menna, P.; Minotti, G
Minimal sampling colistin pharmacokinetics in critically ill patients
2011-01-01 Menna, P; Battistoni, F; Crea, F; Minotti, G; Salvatorelli, E; Dicuonzo, G
Matters of the heart: The case of TNF-alpha targeting drugs
2011-01-01 Cacciapaglia F, F.; Menna, P.; Navarini, L.; Afeltra, A.; Salvatorelli, E.; Minotti, G
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues.
2011-01-01 Cacciapaglia F, F.; Navarini, L.; Menna, P.; Salvatorelli, E.; Minotti, G; Afeltra, A.
Anthracycline Cardiotoxicity
2012-01-01 Menna, P; Gonzalez Paz, O; Chello, M; Covino, E; Salvatorelli, E; Minotti, G
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis
2012-01-01 Salvatorelli, Emanuela; DE TURSI, Michele; Menna, Pierantonio; Carella, Consiglia; Massari, Renato; Colasante, Antonella; Iacobelli, Stefano; Minotti, Giorgio
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin
2012-01-01 Salvatorelli, E; Menna, P; Gonzalez Paz, O; Surapaneni, S; Aukerman, Sl; Chello, M; Covino, E; Sung, V; Minotti, G
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin
2012-01-01 Salvatorelli, E; Menna, P; Surapaneni, S; Aukerman, Sl; Chello, M; Covino, E; Sung, V; Minotti, G
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients
2013-01-01 Salvatorelli, E; Menna, P; Gonzalez Paz, O; Chello, M; Covino, E; Singer, Jw; Minotti, G.
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure
2013-01-01 Cacciapaglia, F; Salvatorelli, E; Navarini, L; Afeltra, A; Menna, P; Minotti, G
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship
2014-01-01 Menna, P; Gallo, P; Vespasiani Gentilucci, U; Salvatorelli, E; Galati, G; Minotti, G; Picardi, A
What is cardiotoxicity?
2014-01-01 Yeh, Et; Salvatorelli, E; Menna, P; Minotti, G
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox
2014-01-01 Cacciapaglia, F; Salvatorelli, E; Minotti, G; Afeltra, A; Menna, P
The concomitant management of cancer therapy and cardiac therapy
2015-01-01 Salvatorelli, E; Menna, P; Cantalupo, E; Chello, M; Wolf, Fi; Minotti, G.
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind
2015-01-01 Salvatorelli, E; Menna, P; Minotti, G
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines.
2016-01-01 Menna, P; Salvatorelli, E; Minotti, G
Do you know pixantrone?
2017-01-01 Minotti, G.; Menna, P.; Salvatorelli, E
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview
2017-01-01 Menna, P.; Salvatorelli, E
Cancer drugs and QT prolongation: weighing risk against benefit
2017-01-01 Menna, P.; Salvatorelli, E; Minotti, G.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile